ClinicalTrials.gg

Program

FGFR2/3 Inhibitor CGT4859

Its studies are mostly in Cholangiocarcinoma, led by Cogent Biosciences.

Furthest: phase 2, since Jan 9, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cogent Biosciences11 open or runningphase 2since Jan 9, 2025Jan 9, 2025Mar 2027phase 2 · NCT06777316

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2025First study: phase 2 study in CholangiocarcinomaFirst studyNCT06777316 · 110 enrolled · United States, Canada

Ahead

  1. Mar 2027Primary completion: phase 2 study in CholangiocarcinomaNCT06777316

TargetBeta

FGFR2 →read by rule
“An orally bioavailable reversible inhibitor of fibroblast growth factor receptor (FGFR) types 2 and 3 (FGFR2/3), ”NCIt, by rule

Other programs on FGFR2

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
lirafugratinibruleelevar-therapeuticsphase 22
KNT-0916rulekinoteck-therapeutics-co-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06777316Cholangiocarcinoma · United States, Canada2Active, not recruitingMar 2027110

How it is read

Names in the registry

  • “CGT4859”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.